Veradigm Takes Action with FY23 Outlook and Major Share Buyback Initiative

  • Veradigm Inc MDRX shares are trading higher Wednesday after the company announced a new share repurchase program under which Veradigm may purchase up to $250 million of its common stock
  • The new share repurchase program does not have a termination date and replaces the previous authorization to repurchase $250 million of common stock, which was almost fully utilized in 2022. 
  • In the fourth quarter of 2022, Veradigm repurchased $57 million of its common stock, bringing its full-year total to $234 million.
  • The company also introduced initial FY23 revenue guidance of $640 million and $660 million, compared to the consensus of $656.84 million.
  • Veradigm expects adjusted EPS of $0.90 and $1.00 versus the consensus of $0.95.
  • Last week, Allscripts Healthcare Solutions Inc changed its name to Veradigm Inc. Allscripts had been transitioning its solutions to the Veradigm brand during 2022.
  • Price Action: MDRX shares are up 3% at $18.35 on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareBuybacksSmall CapMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!